ASX Announcements

15 August 2022

Choroid plexus tissue shipped to Sydney as NTCELL research advances

Living Cell Technologies has advanced its Parkinson’s disease research, with choroid plexus tissue successfully shipped from New Zealand to Australia as part of the third clinical trial of NTCELL. 

29 July 2022

Quarterly Activity Report and Appendix 4C

LCT's Activity and Cashflow (Appendix 4C) report for the June quarter 2022, highlighted by the move to apply the benefits of artificial intelligence towards the Company’s third clinical trial of NTCELL in Parkinson’s disease. 

28 July 2022

Change of Director's Interest Notice - B Tuch and A Kelly

Change of Director's Interest Notice for LCT Directors, Professor Bernie Tuch and Dr Andrew Kelly.

19 July 2022

Ceasing to be a substantial holder

Notice of ceasing to be a substantial holder.

22 June 2022

Investor Presentation - Gold Coast Investment Showcase

Living Cell Technologies' Chief Operating Officer, Dr Belinda Di Bartolo, presented an update on LCT's third clinical trial of NTCELL in Parkinson's disease at the Gold Coast Investment Showcase conference.